Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 13 | 2021 | 272 | 2.740 |
Why?
|
| Neuropsychological Tests | 5 | 2017 | 517 | 1.440 |
Why?
|
| Movement Disorders | 6 | 2013 | 58 | 1.280 |
Why?
|
| Somatoform Disorders | 3 | 2013 | 35 | 0.980 |
Why?
|
| Dystonic Disorders | 2 | 2008 | 9 | 0.600 |
Why?
|
| Behavior Rating Scale | 1 | 2017 | 7 | 0.580 |
Why?
|
| Saccades | 1 | 2017 | 17 | 0.570 |
Why?
|
| Orientation, Spatial | 1 | 2016 | 2 | 0.570 |
Why?
|
| Agnosia | 1 | 2016 | 9 | 0.560 |
Why?
|
| Cognition Disorders | 2 | 2016 | 342 | 0.540 |
Why?
|
| Executive Function | 1 | 2016 | 106 | 0.500 |
Why?
|
| Psychotherapy, Psychodynamic | 1 | 2013 | 2 | 0.460 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 176 | 0.450 |
Why?
|
| Psychotherapy, Brief | 1 | 2013 | 30 | 0.450 |
Why?
|
| Psychometrics | 3 | 2017 | 514 | 0.440 |
Why?
|
| Dementia | 1 | 2012 | 158 | 0.370 |
Why?
|
| Antiparkinson Agents | 2 | 2009 | 34 | 0.350 |
Why?
|
| Vagus Nerve Stimulation | 3 | 2020 | 61 | 0.350 |
Why?
|
| Psychophysiologic Disorders | 2 | 2006 | 20 | 0.340 |
Why?
|
| Carbidopa | 1 | 2009 | 3 | 0.340 |
Why?
|
| Levodopa | 1 | 2009 | 12 | 0.340 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 1851 | 0.340 |
Why?
|
| Locomotion | 3 | 2020 | 135 | 0.340 |
Why?
|
| Reproducibility of Results | 5 | 2017 | 2077 | 0.320 |
Why?
|
| Parkinsonian Disorders | 2 | 2020 | 43 | 0.320 |
Why?
|
| Aged | 12 | 2021 | 14862 | 0.310 |
Why?
|
| Thalamus | 1 | 2008 | 82 | 0.300 |
Why?
|
| Male | 21 | 2021 | 37321 | 0.280 |
Why?
|
| Treatment Outcome | 5 | 2016 | 7029 | 0.280 |
Why?
|
| Disease Progression | 2 | 2021 | 1038 | 0.260 |
Why?
|
| Middle Aged | 13 | 2021 | 21147 | 0.260 |
Why?
|
| Locus Coeruleus | 3 | 2020 | 55 | 0.250 |
Why?
|
| Substantia Nigra | 3 | 2020 | 102 | 0.250 |
Why?
|
| Female | 17 | 2021 | 38074 | 0.240 |
Why?
|
| Double-Blind Method | 5 | 2021 | 1738 | 0.240 |
Why?
|
| Brain Injuries | 1 | 2008 | 268 | 0.240 |
Why?
|
| Movement | 4 | 2012 | 179 | 0.220 |
Why?
|
| Humans | 24 | 2021 | 68618 | 0.220 |
Why?
|
| Cross-Over Studies | 3 | 2013 | 260 | 0.210 |
Why?
|
| Prefrontal Cortex | 1 | 2008 | 640 | 0.210 |
Why?
|
| Adult | 11 | 2017 | 21403 | 0.200 |
Why?
|
| Inosine | 1 | 2021 | 6 | 0.200 |
Why?
|
| Brain | 4 | 2019 | 2176 | 0.200 |
Why?
|
| Encephalitis, Viral | 1 | 2001 | 5 | 0.200 |
Why?
|
| Uric Acid | 1 | 2021 | 37 | 0.190 |
Why?
|
| Virus Diseases | 1 | 2001 | 31 | 0.190 |
Why?
|
| Videotape Recording | 3 | 2009 | 43 | 0.180 |
Why?
|
| Antipsychotic Agents | 1 | 2002 | 247 | 0.170 |
Why?
|
| Receptor, trkB | 1 | 2019 | 27 | 0.170 |
Why?
|
| Vagus Nerve | 1 | 2019 | 90 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 4848 | 0.160 |
Why?
|
| Adrenergic Neurons | 1 | 2017 | 7 | 0.150 |
Why?
|
| Dopaminergic Neurons | 1 | 2017 | 46 | 0.140 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2016 | 14 | 0.140 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2016 | 20 | 0.140 |
Why?
|
| Indans | 1 | 2015 | 20 | 0.130 |
Why?
|
| Cognition | 2 | 2016 | 513 | 0.130 |
Why?
|
| Visual Perception | 1 | 2016 | 124 | 0.130 |
Why?
|
| Oxidopamine | 3 | 2020 | 42 | 0.130 |
Why?
|
| Neural Pathways | 2 | 2008 | 324 | 0.130 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2015 | 124 | 0.120 |
Why?
|
| Ubiquinone | 1 | 2014 | 14 | 0.120 |
Why?
|
| Rats, Long-Evans | 3 | 2020 | 203 | 0.120 |
Why?
|
| Neurologic Examination | 2 | 2005 | 107 | 0.110 |
Why?
|
| Psychomotor Performance | 3 | 2012 | 213 | 0.110 |
Why?
|
| Essential Tremor | 1 | 2012 | 8 | 0.110 |
Why?
|
| GABA Modulators | 1 | 2012 | 26 | 0.110 |
Why?
|
| Norepinephrine | 3 | 2019 | 276 | 0.110 |
Why?
|
| Torticollis | 1 | 2012 | 15 | 0.100 |
Why?
|
| Antioxidants | 1 | 2014 | 304 | 0.100 |
Why?
|
| Parietal Lobe | 1 | 2012 | 59 | 0.100 |
Why?
|
| Sialorrhea | 2 | 2009 | 7 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 84 | 0.100 |
Why?
|
| Functional Laterality | 2 | 2012 | 240 | 0.090 |
Why?
|
| Dopamine | 3 | 2019 | 474 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2012 | 208 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 782 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 2223 | 0.090 |
Why?
|
| Rats | 4 | 2020 | 5300 | 0.090 |
Why?
|
| Tablets | 1 | 2009 | 19 | 0.090 |
Why?
|
| Dyskinesias | 1 | 2009 | 8 | 0.090 |
Why?
|
| Primary Dysautonomias | 1 | 2009 | 1 | 0.080 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 2020 | 71 | 0.080 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2008 | 21 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2009 | 304 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1753 | 0.080 |
Why?
|
| Neostriatum | 2 | 2019 | 60 | 0.080 |
Why?
|
| Observer Variation | 2 | 2006 | 330 | 0.080 |
Why?
|
| Brain Mapping | 2 | 2008 | 532 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 567 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2008 | 107 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 319 | 0.070 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2012 | 413 | 0.070 |
Why?
|
| Research Design | 1 | 2012 | 729 | 0.070 |
Why?
|
| Benzylamines | 2 | 2017 | 28 | 0.070 |
Why?
|
| Axons | 1 | 2007 | 139 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 333 | 0.070 |
Why?
|
| Weights and Measures | 1 | 2005 | 5 | 0.070 |
Why?
|
| Genotype | 1 | 2007 | 786 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 239 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 279 | 0.060 |
Why?
|
| Motor Cortex | 1 | 2006 | 158 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1553 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1140 | 0.060 |
Why?
|
| Psychotherapy | 1 | 2005 | 253 | 0.060 |
Why?
|
| Linear Models | 2 | 2016 | 521 | 0.050 |
Why?
|
| Kidney Calculi | 1 | 2021 | 19 | 0.050 |
Why?
|
| Enterovirus Infections | 1 | 2001 | 6 | 0.050 |
Why?
|
| New York City | 1 | 2001 | 49 | 0.050 |
Why?
|
| West Nile Fever | 1 | 2001 | 7 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 216 | 0.050 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2021 | 82 | 0.050 |
Why?
|
| Animals | 4 | 2020 | 20881 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2001 | 83 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2550 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 2 | 2012 | 329 | 0.040 |
Why?
|
| Azepines | 1 | 2019 | 15 | 0.040 |
Why?
|
| Benzamides | 1 | 2019 | 156 | 0.040 |
Why?
|
| Corpus Striatum | 1 | 2019 | 279 | 0.040 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2016 | 20 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2008 | 249 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 442 | 0.030 |
Why?
|
| Adolescent | 2 | 2005 | 8912 | 0.030 |
Why?
|
| Chaperonin 60 | 1 | 2015 | 10 | 0.030 |
Why?
|
| Monoamine Oxidase | 1 | 2015 | 26 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1593 | 0.030 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2015 | 30 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2015 | 104 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2014 | 3705 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 122 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2015 | 470 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2015 | 317 | 0.030 |
Why?
|
| Pregabalin | 1 | 2012 | 13 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2012 | 82 | 0.030 |
Why?
|
| Sample Size | 1 | 2012 | 79 | 0.020 |
Why?
|
| Hand | 1 | 2012 | 90 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 124 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2358 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1745 | 0.020 |
Why?
|
| Neurons | 1 | 2015 | 881 | 0.020 |
Why?
|
| United States | 2 | 2016 | 7367 | 0.020 |
Why?
|
| PubMed | 1 | 2009 | 21 | 0.020 |
Why?
|
| Constipation | 1 | 2009 | 32 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 689 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2012 | 706 | 0.020 |
Why?
|
| Salivary Glands | 1 | 2007 | 52 | 0.020 |
Why?
|
| Tongue | 1 | 2006 | 20 | 0.020 |
Why?
|
| Thumb | 1 | 2006 | 27 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 652 | 0.020 |
Why?
|
| Foot | 1 | 2006 | 66 | 0.020 |
Why?
|
| Evoked Potentials, Motor | 1 | 2006 | 63 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 1196 | 0.020 |
Why?
|
| Spain | 1 | 2005 | 34 | 0.020 |
Why?
|
| Self Care | 1 | 2008 | 253 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2009 | 297 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 68 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2005 | 107 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 274 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2006 | 296 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2006 | 222 | 0.020 |
Why?
|
| Speech | 1 | 2005 | 118 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 216 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 931 | 0.010 |
Why?
|
| Walking | 1 | 2005 | 241 | 0.010 |
Why?
|
| Anxiety | 1 | 2005 | 422 | 0.010 |
Why?
|
| Depression | 1 | 2005 | 943 | 0.010 |
Why?
|